9AT: ADJUVANT CAPITAL, LP

ADJUVANT CAPITAL, LP

ADJUVANT CAPITAL, LP

Related Companies

Show removed companies

Adviser Profile

As of Date	10/28/2023
Registration status	Registration Changed to ADJUVANT CAPITAL, LP
ADV Location	NEW YORK, NY, United States
Contact Info	917 xxxxxxx
Websites

AUM^*	268,029,399 -23%
of that, discretionary	268,029,399 -23%
Number of Employees	5 -50%
of those in investment advisory functions	4 -56%
Private Fund GAV^*	0
Avg Account Size	134,014,700 -23%
SMA’s	No
Private Funds	0 2

Adviser Type

- Large advisory firm

Client Types

- Pooled investment vehicles

Advisory Activities

- Portfolio management for pooled investment vehicles

Compensation Arrangments

- A percentage of assets under your management
- Performance-based fees

Reported AUM

347M 298M 248M 199M 149M 99M 50M

2020 2021 2022 2023

Discretionary

Non-discretionary

Private Funds

GAV Count

Employees

Brochure Summary

Overview

Advisory Business A. Adjuvant is a Delaware limited partnership that registered with the SEC as an investment adviser effective April 9, 2020. The Firm is principally owned by Glenn Rockman. B. Adjuvant is a discretionary investment manager that seeks long-term capital appreciation through investments in late-stage life science technologies. The Firm manages two pooled investment vehicles, Adjuvant Global Health Technology Fund, L.P., which is a Cayman Island exempted limited partnership (the “Offshore Fund”), and Adjuvant Global Health Technology Fund DE, L.P., a Delaware limited partnership (the “Onshore Fund”), which is managed in parallel alongside the Offshore Fund (both collectively referred to herein as, the “Fund”). Interests in the Fund will be offered privately and generally available only to persons who are “accredited investors” as defined in Regulation D under the Securities Act of 1933, as amended (“Securities Act”) and “qualified purchasers” as defined in Section 2(a)(51) of the Investment Company Act of 1940, as amended (“Investment Company Act”). The Onshore and Offshore Funds’ general partners (“General Partner”) are advisory affiliates of Adjuvant. An investment in the Fund is subject to the investment objectives, terms and conditions outlined in the applicable offering documents, which include, but are not limited to, the confidential private placement memorandum, limited Fund

agreement and subscription materials (collectively, “Governing Documents”). This Brochure does not constitute an offer to sell or the solicitation of an offer to purchase interests in the Fund and the disclosure contained herein shall not be relied on to determine whether an investor (each an “investor” or “Limited Partner”) should purchase interests in the Fund. Any such offer or solicitation will be made solely to qualified investors by means of the Governing Documents. To the extent that there is any conflict between the disclosure contained in this Brochure and the Governing Documents provided to investors, the Governing Documents will govern. While Adjuvant focuses on the strategies and asset classes discussed throughout this Brochure, the Firm does not necessarily limit the types of investments on which it advises. C. To the extent set forth in the Governing Documents, Adjuvant tailors its investment advisory services to be consistent with the Fund’s investment strategy, return profile, concentration limits, time horizon, liquidity mandates and other related objectives, as defined therein. Underlying investors may not impose restrictions on investing in certain securities or types of securities. D. Adjuvant does not participate as a sponsor of or portfolio manager to any wrap fee programs. E. The Firm has $268,029,399 in regulatory assets under management as of December 31, 2022. All of these assets are managed on a discretionary basis.